Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Xenetic Biosciences Inc

NASDAQ XBIO
$3.10 -0.14 -4.32%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
4.02M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-1.14M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
1.54M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-22.31 %

Upcoming events Xenetic Biosciences Inc

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Xenetic Biosciences Inc

Stock analysis Xenetic Biosciences Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.10 -1.36
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
1.02 1.16
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
0.33 -0.80
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.50 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-71.60 -48.24

Price change Xenetic Biosciences Inc per year

2.30$ 4.58$
Min Max

Summary analysis Xenetic Biosciences Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Xenetic Biosciences Inc

Revenue and net income Xenetic Biosciences Inc

All parameters

About company Xenetic Biosciences Inc

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Address:
945 Concord Street, Framingham, MA, United States, 01701
Company name: Xenetic Biosciences Inc
Issuer ticker: XBIO
ISIN: US9840155033
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-06-30
Sector: Healthcare
Industry: Biotechnology
Site: https://www.xeneticbio.com